Avenue Therapeutics Inc logo

Avenue Therapeutics Inc Share Price (NASDAQ: ATXI)

$0.71

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 19 Mar 2025

Check the interactive Avenue Therapeutics Inc Stock chart to analyse performance

Avenue Therapeutics Inc Key Stats

Check Avenue Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.71
Open
$0.38
Market Capitalization
$862.6K
Today's Volume
$173.8K
Revenue TTM
$0.0
Earnings Per Share (EPS)
$24.78
PE Ratio
0.02
Profit Margin
0.0%
Quarterly Earnings Growth YOY
-0.76%
Return On Equity TTM
-535.1%

Global Institutional Holdings in Avenue Therapeutics Inc

  • Name

    Holdings %

  • Ikarian Capital, LLC

    6.82%

  • BOOTHBAY FUND MANAGEMENT, LLC

    2.00%

  • UBS Group AG

    0.39%

  • Tower Research Capital LLC

    0.15%

  • Wells Fargo & Co

    0.02%

Analyst Recommendation on Avenue Therapeutics Inc Stock

Rating
Trend

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Avenue Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Organization
Avenue Therapeutics Inc
Employees
3
CEO
Dr. Alexandra MacLean M.D.
Industry
Health Technology

Key Management of Avenue Therapeutics Inc

NameTitle
Dr. Alexandra MacLean M.D.
CEO & Director
Mr. David Jin
Interim CFO, COO & Corporate Secretary
Dr. Lindsay Allan Rosenwald
Executive Director
Dr. Scott A. Reines M.D., Ph.D.
Interim Chief Medical Officer

Important FAQs about investing in ATXI Stock from India :

What is Avenue Therapeutics Inc share price today?

Avenue Therapeutics Inc share price today is $0.71 as on . Avenue Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Avenue Therapeutics Inc share?

Avenue Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Avenue Therapeutics Inc stock price today i.e. is trending at $0.71, lower by 82.21% versus the 52 week high.

How to invest in Avenue Therapeutics Inc Stock (ATXI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Avenue Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Avenue Therapeutics Inc Shares that will get you 2.1127 shares as per Avenue Therapeutics Inc share price of $0.71 per share as on March 19, 2025 at 12:00 am IST.

What is the minimum amount required to buy Avenue Therapeutics Inc Stock (ATXI) from India?

Indian investors can start investing in Avenue Therapeutics Inc (ATXI) shares with as little as ₹88.689 or $1 (as of October 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹886.89 in Avenue Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on October 31, 2025). Based on Avenue Therapeutics Inc share’s latest price of $0.71 as on March 19, 2025 at 12:00 am IST, you will get 14.0845 shares of Avenue Therapeutics Inc. Learn more about fractional shares .

What are the returns that Avenue Therapeutics Inc has given to Indian investors in the last 5 years?

Avenue Therapeutics Inc stock has given 0.0% share price returns and 19.03% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?